Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | aldehyde dehydrogenase 1 family, member A1 | Starlite/ChEMBL | No references |
Homo sapiens | hydroxysteroid (17-beta) dehydrogenase 10 | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Succinate-semialdehyde dehydrogenase [NADP+] dependent (SSDH) GabD1 | aldehyde dehydrogenase 1 family, member A1 | 501 aa | 456 aa | 33.3 % |
Plasmodium falciparum | 3-oxoacyl-[acyl-carrier-protein] reductase | hydroxysteroid (17-beta) dehydrogenase 10 | 252 aa | 251 aa | 24.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | hypothetical protein | 0.002 | 0.0048 | 0.0052 |
Leishmania major | aldehyde dehydrogenase, mitochondrial precursor | 0.0073 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0037 | 0.3188 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.2048 | 0.2048 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0073 | 1 | 1 |
Mycobacterium tuberculosis | Probable aldehyde dehydrogenase | 0.0073 | 1 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0037 | 0.3188 | 0.3188 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0019 | 0 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 0 | 0.5 |
Echinococcus multilocularis | 3 hydroxyacyl coenzyme A dehydrogenase type 2 | 0.0069 | 0.9249 | 0.9249 |
Brugia malayi | hypothetical protein | 0.003 | 0.2048 | 0.2215 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0069 | 0.9249 | 0.9249 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.2048 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.2048 | 1 |
Loa Loa (eye worm) | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0065 | 0.8384 | 1 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0073 | 1 | 1 |
Mycobacterium tuberculosis | Probable short-chain type dehydrogenase/reductase | 0.0069 | 0.9249 | 0.9249 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.2048 | 1 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0019 | 0 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.2048 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0019 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0037 | 0.3188 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0037 | 0.3188 | 0.3188 |
Entamoeba histolytica | hypothetical protein | 0.0037 | 0.3188 | 1 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0069 | 0.9249 | 0.9249 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.2048 | 1 |
Echinococcus multilocularis | aldehyde dehydrogenase, mitochondrial | 0.0073 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.2048 | 0.2048 |
Leishmania major | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0069 | 0.9249 | 0.9249 |
Brugia malayi | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0069 | 0.9249 | 1 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0073 | 1 | 1 |
Echinococcus granulosus | 3 hydroxyacyl coenzyme A dehydrogenase type 2 | 0.0069 | 0.9249 | 0.9249 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0073 | 1 | 1 |
Toxoplasma gondii | aldehyde dehydrogenase | 0.0073 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.2048 | 0.2443 |
Schistosoma mansoni | hypothetical protein | 0.0037 | 0.3188 | 0.3188 |
Brugia malayi | hypothetical protein | 0.0037 | 0.3188 | 0.3447 |
Entamoeba histolytica | hypothetical protein | 0.0037 | 0.3188 | 1 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0073 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.2048 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 0 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0037 | 0.3188 | 0.3188 |
Schistosoma mansoni | 3-hydroxyacyl-CoA dehydrogenase | 0.0069 | 0.9249 | 0.9249 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0891 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 0.1122 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | = 5.0119 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 70.7946 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | = 89.1251 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase). (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.